LOS ANGELES–(BUSINESS WIRE)–#Duke–DeciBio Consulting, LLC, a precision medicine-focused strategic consulting and market intelligence firm, has added Steve Beuchaw to the firm’s Partnership. Steve will remain based in New York, and establish DeciBio’s presence in the Northeast.

Beuchaw joins DeciBio after a career as a highly ranked Wall Street analyst focusing on the Life Sciences and Medical Devices, most recently at Morgan Stanley and Wolfe Research. Prior to joining DeciBio, he also led teams in Corporate Development and Investor Relations at PHC Holdings. Along the way, he architected data engines and forecasting methods that raised the bar for the use of big data in Life Science Tools research.

As a Partner in New York, Beuchaw will oversee DeciBio’s emerging financial services practice, providing commercial due diligence, financial planning, and market intelligence to financial institutions and investment management companies of all sizes. Additionally, he will provide strategic guidance for executive teams, Boards, and DeciBio’s venture capital initiatives.

According to Beuchaw, “DeciBio’s team brings decades of experience at the intersection of clinical and scientific thinking, a passion for data and analytical rigor, and a huge runway. The team and its client base are growing fast, with the energy of a start-up. I’ve been a champion, partner and client of DeciBio since 2016, and I’m thrilled to come on board.”

DeciBio’s Co-Founding Partner, Stephane Budel, added that “We are excited to welcome Steve to the DeciBio Consulting partnership. Steve’s values and interests align perfectly with DeciBio’s mission to provide strategic insights that accelerate the adoption of precision medicine. His expertise will be invaluable to our M&A practice and the success of our firm. We’ve been fortunate to call him a friend for many years, and we’re excited to continue our discussions and challenge each other as partners.”

In addition to Beuchaw’s core practice, he will also connect a broader set of clients with DeciBio’s expert network, proprietary data tools, and consulting services and capabilities.

As the Managing Director of DeciBio’s New York presence, Beuchaw’s practice will be centrally positioned between DeciBio’s core locations across California and in Europe. “Building out a presence in New York will also give us closer ties to scientific and financial talent and a broader set of key decision makers in life sciences on the East Coast,” notes Beuchaw.

DeciBio’s co-Founding Partner, David Cavanaugh added that “Steve’s strategic mind, determination, and analytical rigor are a combination that will help fuel DeciBio’s rapid expansion throughout the precision medicine ecosystem. We appreciate his track record on Wall Street as a truth seeker who did not conform to the pressures of consensus.”

Beuchaw earned a BA in Business Administration from the University of Texas at Austin and an MBA from Duke University’s Fuqua School of Business. He resides in Larchmont, New York with his wife and daughters.

About DeciBio

DeciBio Consulting (www.decibio.com) is a leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.


Kimberly Stacey